- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 606183, 10 pages
Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity
1Medical Biology Unit, Medical University of Lublin, 20-059 Lublin, Poland
2Human Anatomy Department, Medical University of Lublin, 20-059 Lublin, Poland
3Histology and Embryology Department, Medical University of Lublin, 20-059 Lublin, Poland
4Department of Pulmonolgy, Oncology and Alergology, Medical University of Lublin, 20-059 Lublin, Poland
5Clinical Pathomorphology Department, Medical University of Lublin, 20-059 Lublin, Poland
6Department of Toxicology, Poznan University of Medical Sciences, 60-780 Poznan, Poland
Received 18 April 2012; Revised 17 October 2012; Accepted 24 October 2012
Academic Editor: R. Govindarajan
Copyright © 2012 Jaroslaw Dudka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. M. Fulbright, “Review of cardiotoxicity in pediatric cancer patients: during and after therapy,” Cardiology Research and Practice, vol. 2011, Article ID 942090, 9 pages, 2011.
- M. Feola, O. Garrone, M. Occelli et al., “Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin i and brain natriuretic peptide,” International Journal of Cardiology, vol. 148, no. 2, pp. 194–198, 2011.
- J. Dudka, F. Burdan, A. Korga et al., “The diagnosis of anthracycline-induced cardiac damage and heart failure,” Postępy Higieny i Medycyny Doświadczalnej, vol. 63, pp. 225–233, 2009.
- M. A. Grenier and S. E. Lipshultz, “Epidemiology of anthracycline cardiotoxicity in children and adults,” Seminars in Oncology, vol. 25, no. 4, pp. 72–85, 1998.
- L. J. Steinherz, P. G. Steinherz, C. T. C. Tan, G. Heller, and M. L. Murphy, “Cardiac toxicity 4 to 20 years after completing anthracycline therapy,” Journal of the American Medical Association, vol. 266, no. 12, pp. 1672–1677, 1991.
- G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004.
- A. Korga, J. Dudka, F. Burdan, J. Sliwinska, S. Mandziuk, and K. Daniwdek-Pietryka, “The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and doxorubicin,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 681367, 9 pages, 2012.
- M. F. Xu, P. L. Tang, Z. M. Qian, and M. Ashraf, “Effects by doxorubicin on the myocardium are mediated by oxygen free radicals,” Life Sciences, vol. 68, no. 8, pp. 889–901, 2001.
- J. H. Doroshow, “Effect of anthracycline antibiotics on oxygen radical formation in rat heart,” Cancer Research, vol. 43, no. 2, pp. 460–472, 1983.
- N. R. Bachur, S. L. Gordon, and M. V. Gee, “A general mechanism for microsomal activation of quinone anticancer agents to free radicals,” Cancer Research, vol. 38, no. 6, pp. 1745–1750, 1978.
- J. Vásquez-Vivar, P. Martasek, N. Hogg, B. S. S. Masters, K. A. Pritchard, and B. Kalyanaraman, “Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin,” Biochemistry, vol. 36, no. 38, pp. 11293–11297, 1997.
- M. A. Mansour, A. G. El-Din, M. N. Nagi, O. A. Al-Shabanah, and A. M. Al-Bekairi, “Nω-nitro-L-arginine methylester ameliorates myocardial toxicity induced by doxorubicin,” Journal of Biochemistry and Molecular Biology, vol. 36, no. 6, pp. 593–596, 2003.
- R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair, and T. D. Oberley, “Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?” Antioxidants and Redox Signaling, vol. 9, no. 7, pp. 1001–1008, 2007.
- Y. Zhao, D. McLaughlin, E. Robinson et al., “Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy,” Cancer Research, vol. 70, no. 22, pp. 9287–9297, 2010.
- S. Deng, A. Kruger, A. L. Kleschyov, L. Kalinowski, A. Daiber, and L. Wojnowski, “Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH,” Free Radical Biology and Medicine, vol. 42, no. 4, pp. 466–473, 2007.
- S. B. Yee and C. A. Pritsos, “Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase,” Archives of Biochemistry and Biophysics, vol. 347, no. 2, pp. 235–241, 1997.
- J. Dudka, “The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity,” Postępy Higieny i Medycyny Doświadczalnej, vol. 60, pp. 241–247, 2006.
- A. E. Crib, M. Peyrou, S. Muruganandan, and L. Schneider, “The endoplasmic reticulum in xenobiotic toxicity,” Drug Metabolism Reviews, vol. 37, no. 3, pp. 405–442, 2005.
- J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxicology, vol. 23, no. 1, pp. 15–25, 2007.
- V. A. Sardão, P. J. Oliveira, J. Holy, C. R. Oliveira, and K. B. Wallace, “Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets,” Cell Biology and Toxicology, vol. 25, no. 3, pp. 227–243, 2009.
- U. A. Boelsterli, Mechanistic Toxicology: The Molecular Basis of How Chemicals Disrupt Biological Target, Taylor & Francis, New York, NY, USA, 2003.
- S. Zhou, C. M. Palmeira, and K. B. Wallace, “Doxorubicin-induced persistent oxidative stress to cardiac myocytes,” Toxicology Letters, vol. 121, no. 3, pp. 151–157, 2001.
- J. M. Berthiaume and K. B. Wallace, “Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment,” Cardiovascular Toxicology, vol. 7, no. 3, pp. 178–191, 2007.
- O. A. Al-Shabanah, A. M. Aleisa, M. M. Hafez, and ETAL, “Desferroxamine attenuates doxorubicin induced acute cardiotoxicity through TGF-β/Smad p53 pathway in rat model,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 213112, 7 pages, 2012.
- Y. W. Zhang, J. Shi, Y. J. Li, and L. Wei, “Cardiomyocyte death in doxorubicin-induced cardiotoxicity,” Archivum Immunologiae et Therapia Experimentalis, vol. 57, pp. 435–445, 2009.
- K. L. Thompson, B. A. Rosenzweig, J. Zhang et al., “Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 303–314, 2010.
- A. V. Pointon, T. M. Walker, K. M. Phillips et al., “Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation,” PLoS ONE, vol. 5, no. 9, p. e12733, 2010.
- K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, “Clinical trials of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, pp. 161–169, 2011.
- J. M. Smoliga, J. A. Baur, and H. A. Hausenblas, “Resveratrol and health—a comprehensive review of human clinical trials,” Molecular Nutrition and Food Research, vol. 55, no. 8, pp. 1129–1141, 2011.
- B. B. Aggarwal, A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia, and Y. Takada, “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies,” Anticancer Research, vol. 24, no. 5, pp. 2783–2840, 2004.
- Y. A. Rezk, S. S. Balulad, R. S. Keller, and J. A. Bennett, “Use of Resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart,” American Journal of Obstetrics and Gynecology, vol. 194, no. 5, pp. e23–e26, 2006.
- A. M. Al-Abd, A. M. Mahmoud, G. A. El-Sherbiny, et al., “Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro,” Cell Proliferation, vol. 44, pp. 591–601, 2011.
- M. Sato, N. Maulik, and D. K. Das, “Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants,” Annals of the New York Academy of Sciences, vol. 957, pp. 122–135, 2002.
- S. Das, M. Falchi, A. Bertelli, N. Maulik, and D. K. Das, “Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol,” Arzneimittel-Forschung/Drug Research, vol. 56, no. 10, pp. 700–706, 2006.
- D. J. Luther, V. Ohanyan, P. E. Shamhart et al., “Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma,” Investigational New Drugs, vol. 29, no. 2, pp. 380–391, 2011.
- S. Roy, S. Sannigrahi, S. Majumdar, B. Ghosh, and B. Sarkar, “Resveratrol regulates antioxidant status, inhibits cytokine expression and restricts apoptosis in carbon tetrachloride induced rat hepatic injury,” Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 703676, 2011.
- A. Kumar, C. K. Singh, H. A. Lavoie, D. J. Dipette, and U. S. Singh, “Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders,” Molecular Pharmacology, vol. 80, pp. 446–457, 2011.
- Z. Ungvari, Z. Bagi, A. Feher et al., “Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2,” American Journal of Physiology, vol. 299, no. 1, pp. H18–H24, 2010.
- G. Haskó and P. Pacher, “Endothelial Nrf2 activation: a new target for resveratrol?” American Journal of Physiology, vol. 299, no. 1, pp. H10–H12, 2010.
- Z. Cao and Y. Li, “Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury,” European Journal of Pharmacology, vol. 489, no. 1-2, pp. 39–48, 2004.
- E. D. Brookins Danz, J. Skramsted, N. Henry, J. A. Bennett, and R. S. Keller, “Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway,” Free Radical Biology and Medicine, vol. 46, no. 12, pp. 1589–1597, 2009.
- J. Szumilo, Wpływ Resweratrolu i Kwasu Protokatecholowego na Rozwój Nowotworów Płaskonabłonkowych Przełyku u Szczura Indukowanych Przez N-Nitrozometylobenzyloaminę, Poland Medical University of Lublin, Lublin, Poland, 2007.
- J. A. Crowell, P. J. Korytko, R. L. Morrissey, T. D. Booth, and B. S. Levine, “Resveratrol-associated renal toxicity,” Toxicological Sciences, vol. 82, no. 2, pp. 614–619, 2004.
- D. Lebrecht, A. Geist, U. P. Ketelsen, J. Haberstroh, B. Setzer, and U. A. Walker, “Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats,” British Journal of Pharmacology, vol. 151, no. 6, pp. 771–778, 2007.
- J. J. Lemasters and A. L. Nieminen, Mitochondria in pathogenesis, Academic/Plenum, New York, NY, USA, 2001.
- B. A. Johnson, M. S. Cheang, and G. J. Goldenberg, “Comparison of adriamycin uptake in chick embryo heart and liver cells and murine L5178Y lymphoblasts in vitro: role of drug uptake in cardiotoxicity,” Cancer Research, vol. 46, no. 1, pp. 218–223, 1986.
- G. Y. Wang, Y. M. Wang, L. N. Zhang et al., “Effect of resveratrol on heart function of rats with adriamycin-induced heart failure,” Zhongguo Zhongyao Zazhi, vol. 32, no. 15, pp. 1563–1565, 2007.
- A. Kasdallah-Grissa, B. Mornagui, E. Aouani et al., “Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver,” Life Sciences, vol. 80, no. 11, pp. 1033–1039, 2007.
- P. Vitaglione, B. Ottanelli, S. Milani, F. Morisco, N. Caporaso, and V. Fogliano, “Dietary trans-resveratrol bioavailability and effect on CCl 4-induced liver lipid peroxidation,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 618–622, 2009.
- G. Şener, N. Topaloǧlu, A. Özer Şehirli, F. Ercan, and N. Gedik, “Resveratrol alleviates bleomycin-induced lung injury in rats,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 6, pp. 642–649, 2007.
- M. Murias, W. Jäger, N. Handler et al., “Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship,” Biochemical Pharmacology, vol. 69, no. 6, pp. 903–912, 2005.
- S. S. Leonard, C. Xia, B. H. Jiang et al., “Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses,” Biochemical and Biophysical Research Communications, vol. 309, no. 4, pp. 1017–1026, 2003.
- M. Kitada, S. Kume, N. Imaizumi, and D. Koya, “Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1—independent pathway,” Diabetes, vol. 60, no. 2, pp. 634–643, 2011.
- J. Dudka, J. Jodynis-Liebert, E. Korobowicz et al., “Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study,” Basic and Clinical Pharmacology and Toxicology, vol. 97, no. 2, pp. 74–79, 2005.
- A. Maier-Salamon, M. Böhmdorfer, T. Thalhammer, T. Szekeres, and W. Jaeger, “Hepatic glucuronidation of resveratrol: interspecies comparison of enzyme kinetic profiles in human, mouse, rat, and dog,” Drug Metabolism and Pharmacokinetics, vol. 26, pp. 364–373, 2011.
- R. D. Olson and P. S. Mushlin, “Doxorubicin cardiotoxicity: analysis of prevailing hypotheses,” FASEB Journal, vol. 4, no. 13, pp. 3076–3086, 1990.
- Y. Chen, J. T. Saari, and Y. J. Kang, “Weak antioxidant defenses make the heart a target for damage in copper-deficient rats,” Free Radical Biology and Medicine, vol. 17, no. 6, pp. 529–536, 1994.
- R. H. M. Julicher, L. Sterrenberg, G. R. M. M. Haenen, A. Bast, and J. Noordhoek, “The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat,” Archives of Toxicology, vol. 61, no. 4, pp. 275–281, 1988.
- B. Piver, M. Fer, X. Vitrac et al., “Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes,” Biochemical Pharmacology, vol. 68, no. 4, pp. 773–782, 2004.
- R. M. Green, M. Graham, M. R. O'Donovan, J. K. Chipman, and N. J. Hodges, “Subcellular compartmentalization of glutathione: correlations with parameters of oxidative stress related to genotoxicity,” Mutagenesis, vol. 21, no. 6, pp. 383–390, 2006.